Open main menu

Psychiatrienet β

Changes

Combining-Lamotrigine-Valproic acid

294 bytes removed, 10:50, 23 April 2010
no edit summary
| add = valproic acid
| info =
* Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
| start =
| cave =
* Valproate can increase lamotrigine plasma levels significantly by inhibiting lamotrigine’s glucuronidation. This effect of valproate is dose-dependent.<ref name=”bazire”> Bazire S, Psychotropic Drug Directory 2007, HealthComm UK Limited, Aberdeen, 2007. </ref>
* Very slow titration of lamotrigine is recommended because reports of lamotrigine-related skin rashes. <ref> {{Pubmed|16225978|Chang CC at al, Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsychopharmacol Neuropsych. Biol Psychiatry. 2006 Jan;30(1):147-50}}</ref>
}}
326
edits